osteoarthritis News
-
KiOmed Pharma obtains CE mark and signs a License and Supply Agreement
KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a License and Supply Agreement with TRB Chemedica, a leading pharmaceutical and biotechnology company. KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a ...
-
Gelexir becomes Gelmetix
We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix. This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: ...
-
A new study confirming correlation between Biomechanical Markers and clinical outcomes in knee OA patients
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
By Emovi
-
Symic Bio Announces First Patient Enrolled in Osteoarthritis Phase 2b Study
SAN FRANCISCO, March 1, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the first patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a doubleblinded, randomized controlled trial investigating Symic Bio’s DMOAD (disease-modifying OA drug) candidate, SB-061 vs. ...
-
Symic Bio Announces Last Patient Enrolled in Osteoarthritis Phase 2b Study MODIFY3
DENMARK & SAN FRANCISCO, October 8, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the last patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symic Bio’s DMOAD (diseasemodifying OA drug) candidate, ...
-
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits ...
-
Why are O2 levels in Osteoarthritis studies important? Scientific Application Bulletin
SCI-tive is a physiologically relevant, protected and controlled environment workstation for researchers that need a bit more space that can be, if desired, expanded to a multi-chamber GMP-level controlled ...
By Baker
-
Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis
Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical programs and any required preclinical work necessary for regulatory approval Sun Pharma has worldwide commercialization & manufacturing rights ...
-
Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
-
KiOmed Pharma and moveUP Partner to Develop and Market a Companion Healthcare Application for Personalised Treatment of Osteoarthritis
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, while exclusive ...
-
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
First tahoe unicompartmental knee system (TUKS) procedure
El Dorado Hills, CA, June 2022 – Shalby Advanced Technologies, (DBA Consensus Orthopedics) proudly reports its first implantation of The Tahoe Uni-compartmental Knee System (TUKS), in Plano,Texas on June 2, 2022. The surgery was performed by Dr. Richard Reitman and was a great surgical success. This surgery marks the culmination of over 6 years of research and development. The patient, a 52 ...
-
FDA Premarket Approval Granted for DT MedTech’s Hintermann Series H3 Total Ankle Replacement System
DT MedTech, LLC(DTM) announced today that the Hintermann Series H3 (H3) Total Ankle Replacement (TAR) System has received premarket approval (PMA) from the U.S. Food and Drug Administration. The H3 is a three-piece, mobile-bearing implant. The Hintermann Series H3 Total Ankle Replacement System is indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to ...
-
DT MedTech Announces Successful Implantations of the New Hintermann Series H2 Total Ankle Replacement Prosthesis
DT MedTech, LLC (DTM) announced today that Prof. Beat Hintermann, world-renowned foot and ankle surgeon and developer of the new, two-component, semi-constrained total ankle prosthesis, Hintermann Series H2 Total Ankle Replacement System, has successfully implanted five H2 devices in patients in Liestal, Switzerland. Four of the procedures were primary total ankle replacements and the fifth was a ...
-
YourKnee by Rejoint has received the Conformité Européene (CE) Mark
Rejoint provides the holistic approach for total knee replacement called YourKnee™ which has received the Conformité Européene (CE) Mark in January 2020. The CE marking confirms that YourKnee meets the requirements of the European Medical Devices Directive, which allows Rejoint to commercialize YourKnee and all its disposable products across the European Union and other CE ...
By Rejoint SRL
-
Cytex Founding Scientists Receive Top Award in Orthopaedic Research
The American Academy of Orthopedic Surgeons (AAOS) today announced that the 2021 Kappa Delta Elizabeth Winston Lanier Award has been granted to Cytex Therapeutics founders Drs. Farshid Guilak, Bradley Estes and Frank Moutos. The Kappa Delta Awards recognize research in musculoskeletal disease or injury with potential to advance patient care and are the highest awards in the field of orthopaedic ...
-
KiOmed Pharma reports promising long-term results in a new European multi centric survey Treatment of Advanced Knee OsteoArthritis
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with advanced stage OA. ‘This ...
-
DT MedTech Announces the First US Implantation of the Hintermann Series H3 Total Ankle Replacement System at the Lakewood Ranch Medical Center
DT MedTech, LLC (DTM) announced today that the first Hintermann Series H3 Total Ankle Replacement System (H3) has been successfully implanted in a patient in the United States. The surgery was performed, implanting the H3, three-component, non-cemented, non-constrained total ankle replacement system, at Lakewood Ranch Medical Center in Sarasota, Florida by Dr. James Cottom of Florida Orthopedic ...
-
Gelmetix signs collaboration for development of Knee Osteoarthritis product
Stemmatters and Gelmetix have established an agreement to develop an innovative hydrogel based device for the treatment of cartilage lesions. The partnership established focuses on the pre-clinical development of the new device towards clinical studies in human patients and subsequent market authorization. The new medical device aims to ensure a significant advance in the treatment of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you